Literature DB >> 28640644

Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats.

Yan Wang1, Fei Zhang1, Yu Liu1, Sha Yin1, Xuefen Pang2, Zhidong Li1, Zehui Wei1.   

Abstract

PURPOSE: To investigate the effect and mechanism of nebivolol on aortic remodeling in N-nitro-l-arginine methyl ester (l-NAME)-induced hypertension.
METHODS: Male Sprague-Dawley rats were treated with equal volumes of drinking water or l-NAME (60 mg/kg/day), alone or in combination with nebivolol (8 mg/kg/day) or atenolol (80 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure (SBP), aortic morphometry, plasma nitric oxide (NO) levels, nitric oxide synthase (NOS) activity, and relaxation of aorta to acetylcholine were determined. Protein expression of endothelial NOS (eNOS), Akt, and NADPH oxidase (Nox) was evaluated.
RESULTS: l-NAME-treated rats showed an elevated SBP associated with aortic remodeling. l-NAME-treated rats showed reduced plasma NO levels and NOS activity and increased reactive oxygen species (ROS). Protein expression of eNOS, eNOS phosphorylated at Ser1177 (p-eNOS), Akt, and Akt phosphorylated at Ser473 (p-Akt) decreased, whereas that of Nox2, Nox4, and p22phox increased in the aortas from l-NAME-treated rats. Nebivolol treatment reduced SBP and ameliorated aortic remodeling. The effects of nebivolol were accompanied by increasing NO levels, NOS activity, and expression of eNOS, p-eNOS, Akt, and p-Akt, as well as reduction of ROS generation and Nox2, Nox4, and p22phox expression. These effects of nebivolol were not reproduced by atenolol.
CONCLUSION: Our data indicate a protective role of nebivolol on the high blood pressure and vascular remodeling induced by l-NAME. The beneficial vascular effect of nebivolol is mediated by the upregulation of eNOS and inhibition of oxidative stress.

Entities:  

Keywords:  Aorta; L-NAME; hypertension; nebivolol; remodeling

Mesh:

Substances:

Year:  2017        PMID: 28640644     DOI: 10.1080/10641963.2017.1306539

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  9 in total

1.  Inhibition of eNOS Partially Blunts the Beneficial Effects of Nebivolol on Angiotensin II-Induced Signaling in H9c2 Cardiomyoblasts.

Authors:  Rukhsana Gul; Nouf Alsalman; Assim A Alfadda
Journal:  Curr Issues Mol Biol       Date:  2022-05-10       Impact factor: 2.976

2.  Enhanced A1 adenosine receptor-induced vascular contractions in mesenteric artery and aorta of in L-NAME mouse model of hypertension.

Authors:  Vishal R Yadav; Bunyen Teng; S Jamal Mustafa
Journal:  Eur J Pharmacol       Date:  2018-10-19       Impact factor: 4.432

Review 3.  Oxidative Stress, GTPCH1, and Endothelial Nitric Oxide Synthase Uncoupling in Hypertension.

Authors:  Yin Wu; Ye Ding; Tharmarajan Ramprasath; Ming-Hui Zou
Journal:  Antioxid Redox Signal       Date:  2020-05-27       Impact factor: 8.401

4.  Nebivolol Prevents Up-Regulation of Nox2/NADPH Oxidase and Lipoperoxidation in the Early Stages of Ethanol-Induced Cardiac Toxicity.

Authors:  Gabriel T do Vale; Carla B P da Silva; Arthur H Sousa; Natália A Gonzaga; Juliana M Parente; Katiúscia M Araújo; Michele M Castro; Carlos R Tirapelli
Journal:  Cardiovasc Toxicol       Date:  2020-10-16       Impact factor: 3.231

5.  Evaluation of blood vessel injury, oxidative stress and circulating inflammatory factors in an L-NAME-induced preeclampsia-like rat model.

Authors:  Wen Shu; Hanying Li; Hao Gong; Mei Zhang; Xiulong Niu; Yongqiang Ma; Xin Zhang; Wei Cai; Guohong Yang; Maoti Wei; Ning Yang; Yuming Li
Journal:  Exp Ther Med       Date:  2018-05-24       Impact factor: 2.447

Review 6.  Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients.

Authors:  Francesco Sabbatino; Valeria Conti; Luigi Liguori; Giovanna Polcaro; Graziamaria Corbi; Valentina Manzo; Vincenzo Tortora; Chiara Carlomagno; Carmine Vecchione; Amelia Filippelli; Stefano Pepe
Journal:  Life (Basel)       Date:  2021-01-30

7.  Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats.

Authors:  Julieta S Del Mauro; Paula D Prince; Yanina Santander Plantamura; Miguel A Allo; Luciano Parola; Nahuel Fernandez Machulsky; Marcela A Morettón; Eliana P Bin; Germán E González; Facundo M Bertera; Andrea Carranza; Gabriela Berg; Carlos A Taira; Martín Donato; Diego A Chiappetta; Ariel H Polizio; Christian Höcht
Journal:  Hypertens Res       Date:  2021-02-22       Impact factor: 3.872

Review 8.  The Antioxidant Therapy: New Insights in the Treatment of Hypertension.

Authors:  Daniela Sorriento; Nicola De Luca; Bruno Trimarco; Guido Iaccarino
Journal:  Front Physiol       Date:  2018-03-21       Impact factor: 4.566

9.  Hiding in Plain Sight: Nebivolol Exhibits Compelling Tocolytic Properties.

Authors:  Scott D Barnett; Iain L O Buxton
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.